The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | ARTEMIS-008: risvutatug rezetecan versus topotecan in relapsed SCLC
Anne Chiang, MD, PhD, Yale University School of Medicine, New Haven, CT, presents primary results from Phase III ARTEMIS-008 (NCT06498479) of risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, versus topotecan in patients with relapsed small cell lung cancer (SCLC) following platinum-based chemotherapy. Ris-Rez demonstrated statistically significant and clinically meaningful improvements in overall survival, progression-free survival, objective response rate, and disease control rate, with a more favourable safety profile than topotecan, supporting its potential as a new standard of care in relapsed SCLC. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
